Unblock your protein supply
Supply chains offer many opportunities for recombinant proteins that are held up by technical difficulties associated with quality, cost, efficiency and manufacturing at scale. Large and untapped markets may have specific requirements that other technologies cannot deliver.
Phenotypeca’s QTL technology is built on decades of research and hard-won expertise in optimised strain breeding, screening and genomics, enabling us to resolve manufacturing issues that you might assume cannot be fixed.
Our work to lower the cost of certain vaccines with support from the Bill & Melinda Gates Foundation has demonstrated that our approach can deliver optimised strains much faster and more reliably than standard methods – and at a much lower cost. Crucially, everything we do is designed to enable manufacturing at scale while minimising the quantity of plant required and using safe, sustainable, animal-free bioprocesses without any toxic chemicals or antibiotics.
Let us solve your problem
The technical obstacles holding up a supply chain opportunity might involve insufficient titre, yield losses, plasmid or genetic instability, post-translation modifications, excessive purification steps, toxic waste products, immunogenicity sensitivity or inconsistent quality and quantity. In all these cases, we have swift and validated solutions that warrant a discussion.